US FDA grants Breakthrough Therapy Designation for Takeda’s Pevonedistat
The investigational drug is for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
pevonedistat
Key pipeline advancements to propel myelodysplastic syndromes market to $2.4 bn by 2028: GlobalData
Despite the recent surge of development within the MDS space, KOLs argue that the level of unmet need remained dire.